- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- FDA advisory panel to consider OTC status of NSAIDs
- Diplomat becomes distributor of recently approved cancer drug
SILVER SPRING, Md. — The Food and Drug Administration has approved the first generic version of a drug for treating and preventing osteoporosis in women after menopause, the agency said Monday.
The FDA announced the approval of ibandronate tablets in the 150-mg strength made by Apotex, Orchid Healthcare and Mylan Pharmaceuticals. Genentech makes the branded version of the drug.
"Men as well as women are affected by osteoporosis, a disease that can be prevented and treated," FDA Office of Pharmaceutical Science deputy director Keith Webber said. "For people who must manage their health conditions over time, it is important to have affordable treatment options."